{
    "clinical_study": {
        "@rank": "57115", 
        "arm_group": {
            "arm_group_label": "Miravirsen", 
            "description": "Subjects who were enrolled in and received miravirsen doses in study SPC3649-207 will be observed for safety and efficacy in the 3-year long-term extension study SPC3649-207E. No study medication will be given during this extension study."
        }, 
        "biospec_descr": {
            "textblock": "Plasma"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Study SPC3649-207E is designed as an extension study to the prior protocol to provide\n      additional long-term safety and efficacy information for subjects participating in Study\n      SPC3649-207."
        }, 
        "brief_title": "Long-term Extension to Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - Participated in study SPC3649-207\n\n        Exclusion Criteria:\n\n        - Received investigational drug therapy after discontinuation, termination, or successful\n        completion of study SPC3649-207"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "21 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Null responder subjects with CHC genotype 1 virus infection who have participated in study\n        SPC3649-207."
            }
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02031133", 
            "org_study_id": "SPC3649-207E"
        }, 
        "intervention": {
            "arm_group_label": "Miravirsen", 
            "intervention_name": "Miravirsen", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferons", 
                "Ribavirin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Antisense", 
            "miR-122 antagonist", 
            "host factor", 
            "Chronic hepatitis C", 
            "Hepatitis C"
        ], 
        "lastchanged_date": "January 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Juan", 
                    "country": "Puerto Rico", 
                    "zip": "00927"
                }, 
                "name": "Fundacion de Investigation de Diego"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Long-term Extension to a Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin in Subjects With Chronic Hepatitis C (CHC) Virus Genotype 1 Infection", 
        "other_outcome": {
            "description": "The miR-122 seed sites in HCV RNA from subjects following viral breakthrough or relapse will be subjected to genotypic sequence analysis.", 
            "measure": "Viral resistance analysis through end of study.", 
            "safety_issue": "No", 
            "time_frame": "36 months"
        }, 
        "overall_official": {
            "affiliation": "Fundacion de Investigacion de Diego", 
            "last_name": "Maribel Rodriguez-Torres, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety and tolerability will be assessed by evaluation of liver ultrasound, physical examinations, vital signs, and routine laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis).", 
            "safety_issue": "Yes", 
            "time_frame": "36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02031133"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change in HCV RNA level from baseline through end of study.", 
            "safety_issue": "No", 
            "time_frame": "36 months"
        }, 
        "source": "Santaris Pharma A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Santaris Pharma A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}